132 related articles for article (PubMed ID: 32195186)
1. Real-World Data of Triplet Combination of Trastuzumab, Lapatinib, and Chemotherapy in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study.
Li Y; Gong C; Lu Q; Zhou Z; Luo T; Li W; Li G; Ge R; Xu F; Wang B
Front Oncol; 2020; 10():271. PubMed ID: 32195186
[No Abstract] [Full Text] [Related]
2. Primary results of ELAINA: a randomized, multicenter, open-label, phase III study of the efficacy and safety of trastuzumab emtansine
Wang X; Li W; Yin Y; Tong Z; Zhang Q; Zheng H; Shao Z; Li H; Yang J; Feng J; Wu F; Lamour F; Restuccia E; Jiang Z
Transl Breast Cancer Res; 2023; 4():3. PubMed ID: 38751488
[TBL] [Abstract][Full Text] [Related]
3. Real-world data of triplet combination of pyrotinib, trastuzumab, and chemotherapy in HER2-positive metastatic breast cancer: a multicenter, retrospective study.
You S; Sang D; Xu F; Luo T; Yuan P; Xie Y; Wang B
Ther Adv Med Oncol; 2023; 15():17588359231217972. PubMed ID: 38145113
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of margetuximab plus chemotherapy
Zhang Q; Ouyang Q; Li W; Chiu J; Yan M; Lu YS; Sun S; Li H; Du Y; Wang X; Sun T; Yin Y; Wang H; Ye F; Shen K; Wang J; Pan Y; Wang S; Yang J; Wu X; Dai MS; Cheng J; Teng Y; Su F; Wu X; He J; Fu P; Yang L; Xin Y; Wang X; Jiang Z
Transl Breast Cancer Res; 2022; 3():31. PubMed ID: 38751523
[TBL] [Abstract][Full Text] [Related]
5. Comparing pyrotinib with trastuzumab and pertuzumab with trastuzumab for HER2-positive metastatic breast cancer: a retrospective, multicenter analysis.
You S; Xie Y; Sang D; Luo T; Yuan P; Xu F; Wang B
Front Endocrinol (Lausanne); 2023; 14():1325540. PubMed ID: 38149099
[TBL] [Abstract][Full Text] [Related]
6. In era of immunotherapy: the value of trastuzumab beyond progression in patients with trastuzumab-resistant HER2-positive advanced or metastatic gastric cancer.
Wang H; Nie C; Xu W; Li J; Gou H; Lv H; Chen B; Wang J; Liu Y; He Y; Zhao J; Chen X
Therap Adv Gastroenterol; 2024; 17():17562848241245455. PubMed ID: 38617123
[TBL] [Abstract][Full Text] [Related]
7. Pyrotinib Combined with Vinorelbine in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Single-Arm, Prospective Study.
Jiang K; Hong R; Xia W; Lu Q; Li L; Huang J; Shi Y; Yuan Z; Zheng Q; An X; Xue C; Huang J; Bi X; Chen M; Zhang J; Xu F; Wang S
Cancer Res Treat; 2024 Apr; 56(2):513-521. PubMed ID: 37846468
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of utidelone plus capecitabine in advanced first-line therapy for metastatic breast cancer: A multicenter real-world study.
Bi P; Wang X; Liu R; Li X; Wei S; Zhao J; Tan X; Zhang F; Mao Q; Zhang Y; Tang B; Xun X; Guo R; Zheng K; Zhou S; Tang S
Surg Open Sci; 2023 Dec; 16():171-183. PubMed ID: 38026829
[TBL] [Abstract][Full Text] [Related]
9. Tucatinib Combination Treatment After Trastuzumab-Deruxtecan in Patients With ERBB2-Positive Metastatic Breast Cancer.
Frenel JS; Zeghondy J; Guérin-Charbonnel C; Mailliez A; Volant E; Poumeaud F; Patsouris A; Arnedos M; Bailleux C; Cabal J; Galland L; de Nonneville A; Guiu S; Dalenc F; Pistilli B; Bachelot T; Pierga JY; Le Du F; Bocquet F; Larrouquere L; Loirat D
JAMA Netw Open; 2024 Apr; 7(4):e244435. PubMed ID: 38568692
[TBL] [Abstract][Full Text] [Related]
10. Long-term Outcome Analysis of Pyrotinib in Patients With HER2-Positive Metastatic Breast Cancer and Brain Metastasis: A Real-World Study.
Liang X; Gui X; Yan Y; Di L; Liu X; Li H; Song G
Oncologist; 2024 Feb; 29(2):e198-e205. PubMed ID: 37589217
[TBL] [Abstract][Full Text] [Related]
11. Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Huober J; Weder P; Ribi K; Thürlimann B; Thery JC; Li Q; Vanlemmens L; Guiu S; Brain E; Grenier J; Dalenc F; Levy C; Savoye AM; Müller A; Membrez-Antonioli V; Gérard MA; Lemonnier J; Hawle H; Dietrich D; Boven E; Bonnefoi H;
JAMA Oncol; 2023 Oct; 9(10):1381-1389. PubMed ID: 37561451
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab Biosimilar (HLX02), Pertuzumab Plus Chemotherapy in Patients with HER2-Positive Metastatic Breast Cancer after Progression of Trastuzumab: A Prospective, Phase II Study.
Zhang R; Liu X; Song G; Zhang Y; Li H
Cancer Res Treat; 2023 Dec; ():. PubMed ID: 38147816
[TBL] [Abstract][Full Text] [Related]
13. Retrospective Analysis of Pyrotinib-Based Therapy for Metastatic Breast Cancer: Promising Efficacy in Combination with Trastuzumab.
Gu Q; Zhu M; Wang Y; Gu Y
Breast Cancer (Dove Med Press); 2024; 16():253-268. PubMed ID: 38812479
[TBL] [Abstract][Full Text] [Related]
14. Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study.
Botticelli A; Caputo R; Scagnoli S; Pisegna S; De Laurentiis M; Curigliano G; Lambertini M; Pantano F; Palazzo A; Paris I; Vernieri C; Tedesco B; Giampaglia M; Palleschi M; Ballatore Z; Alesini D; D'Auria G; Fabbri A; Rossi L; Verrazzo A; Scafetta R; Marinelli D; Sposetti C; Barberi V; Strigari L; Marchetti P; Santini D; Fabi A
Oncologist; 2024 Apr; 29(4):303-310. PubMed ID: 37995313
[TBL] [Abstract][Full Text] [Related]
15. A nationwide real-world study for evaluation of effectiveness and safety of T-DM1 in patients with HER2-positive metastatic breast cancer in Korea (KCSG BR19-15).
Baek SK; Jeong JH; Jung K; Ahn HK; Kim MH; Sohn J; Park IH; Ahn JS; Lee DW; Im SA; Sim SH; Lee KS; Hyun Kim J; Shim HJ; Chae Y; Koh SJ; Lee H; Lee J; Byun JH; Seol Y; Lee EM; Jee HJ; An H; Park EB; Suh YJ; Lee KE; Park YH;
Ther Adv Med Oncol; 2024; 16():17588359231225029. PubMed ID: 38288157
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological characteristics, evolution, treatment pattern and outcomes of hormone-receptor-positive/HER2-low metastatic breast cancer.
You S; Gong C; Li Y; Xie Y; Li Y; Zhao Y; Wang B
Front Endocrinol (Lausanne); 2023; 14():1270453. PubMed ID: 37881502
[TBL] [Abstract][Full Text] [Related]
17. Real-world patient characteristics, treatment patterns, and clinical outcomes associated with tucatinib therapy in HER2-positive metastatic breast cancer.
Kaufman PA; Neuberger E; Schwartz NRM; Wang S; Liu Y; Hsu LI; Bartley K; Blahna MT; Pittner BT; Wong G; Anders C
Front Oncol; 2023; 13():1264861. PubMed ID: 37849811
[TBL] [Abstract][Full Text] [Related]
18. Eribulin combined with antiangiogenic agents in women with HER2-negative metastatic breast cancer: a retrospective multicenter study.
Jiang M; Shao B; Wan D; Liu J; He M; Chai Y; Sang D; Wang J; Ma F; Fan Y; Yuan P; Xu B; Li Q
Ther Adv Med Oncol; 2023; 15():17588359231204856. PubMed ID: 37841751
[TBL] [Abstract][Full Text] [Related]
19. Real-world Outcomes of Dual HER2 Blockade Therapy in Metastatic HER2-Positive Breast Cancer: from Induction to Maintenance.
Križić M; Popović M; Silovski T; Grbin D; Dedić Plavetić N
Drugs Real World Outcomes; 2024 Jun; ():. PubMed ID: 38879832
[TBL] [Abstract][Full Text] [Related]
20. Effect of capecitabine as monotherapy for HER2 normal metastatic breast cancer.
Knudsen AM; Modvig MW; Vogsen M; Kodahl AR
Med Oncol; 2024 Mar; 41(5):99. PubMed ID: 38538985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
